Imam Mohamed A, Holton James, Horriat Saman, Negida Ahmed S, Grubhofer Florian, Gupta Rohit, Narvani Ali, Snow Martyn
Department of Trauma and Orthopaedics, Faculty of Medicine, Suez Canal University, Circular road, Ismailia 41111, Egypt - The Royal Orthopaedic Hospital, Birmingham B31 2AP, UK.
The Royal Orthopaedic Hospital, Birmingham B31 2AP, UK - Birmingham University, Birmingham B15 2TT, UK.
SICOT J. 2017;3:58. doi: 10.1051/sicotj/2017039. Epub 2017 Oct 9.
Tendon pathologies are a group of musculoskeletal conditions frequently seen in clinical practice. They can be broadly classified into traumatic, degenerative and overuse-related tendinopathies. Rotator cuff tears, Achilles tendinopathy and tennis elbow are common examples of these conditions. Conventional treatments have shown inconsistent outcomes and might fail to provide satisfactory clinical improvement. With the growing trend towards the use of mesenchymal stem cells (MSCs) in other branches of medicine, there is an increasing interest in treating tendon pathologies using the bone marrow MSC. In this article, we provide a systematic literature review documenting the current status of the use of bone marrow aspirate concentrate (BMAC) for the treatment of tendon pathologies. We also asked the question on the safety of BMAC and whether there are potential complications associated with BMAC therapy. Our hypothesis is that the use of BMAC provides safe clinical benefit when used for the treatment of tendinopathy or as a biological augmentation of tendon repair. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist while preparing this systematic review. A literature search was carried out including the online databases of PubMed, EMBASE, ClinicalTrial.gov and the Cochrane Library from 1960 to the end of May 2015. Relevant studies were selected and critically appraised. Data from eligible studies were extracted and classified per type of tendon pathology. We included 37 articles discussing the application and use of BMAC for the treatment of tendon pathologies. The Critical Appraisal Skills Program (CASP) appraisal confirmed a satisfactory standard of 37 studies. Studies were sub-categorised into: techniques of extraction, processing and microscopic examination of BMAC (n = 18), where five studies looked at the evaluation of aspiration techniques (n = 5), augmentation of rotator cuff tears (n = 5), augmentation of tendo-achilles tendon (n = 1), treatment of gluteal tendon injuries (n = 1), management of elbow epicondylitis (n = 2), management of patellar tendinopathy (n = 1) and complications related to BMAC (n = 5). Multiple experimental studies investigated the use of BMAC for tendon repair; nonetheless, there are only limited clinical studies available in this field. Unfortunately, due to the scarcity of studies, which were mainly case series, the current level of evidence is weak. We strongly recommend further future randomised controlled studies in this field to allow scientists and clinicians make evidence-based conclusions.
肌腱病变是临床实践中常见的一组肌肉骨骼疾病。它们大致可分为创伤性、退行性和过度使用相关的肌腱病。肩袖撕裂、跟腱病和网球肘就是这些疾病的常见例子。传统治疗方法的效果并不一致,可能无法带来令人满意的临床改善。随着间充质干细胞(MSC)在医学其他领域的应用趋势不断增加,人们对使用骨髓间充质干细胞治疗肌腱病变的兴趣也日益浓厚。在本文中,我们提供了一项系统的文献综述,记录了使用骨髓抽吸浓缩物(BMAC)治疗肌腱病变的现状。我们还探讨了BMAC的安全性问题以及BMAC治疗是否存在潜在并发症。我们的假设是,使用BMAC治疗肌腱病或作为肌腱修复的生物增强手段能带来安全的临床益处。在准备这项系统综述时,我们遵循了系统评价和Meta分析的首选报告项目(PRISMA)清单。我们进行了文献检索,包括1960年至2015年5月底的PubMed、EMBASE、ClinicalTrial.gov和Cochrane图书馆在线数据库。选择并严格评估了相关研究。从符合条件的研究中提取数据,并根据肌腱病变类型进行分类。我们纳入了37篇讨论BMAC治疗肌腱病变的应用和使用情况的文章。批判性评估技能计划(CASP)评估证实这37项研究的标准令人满意。研究分为以下几类:BMAC的提取、处理和显微镜检查技术(n = 18),其中五项研究关注抽吸技术的评估(n = 5)、肩袖撕裂的增强(n = 5)、跟腱增强(n = 1)、臀肌腱损伤的治疗(n = 1)、肘外侧炎的管理(n = 2)、髌腱病的管理(n = 1)以及与BMAC相关的并发症(n = 5)。多项实验研究探讨了BMAC在肌腱修复中的应用;然而,该领域的临床研究有限。不幸的是,由于研究稀缺,且主要是病例系列研究,目前的证据水平较低。我们强烈建议该领域未来进一步开展随机对照研究,以便科学家和临床医生得出基于证据的结论。